Charles River Laboratories (CRL) fundamentals: P/E, valuation, undervalued?
Charles River Laboratories · Health Care · ref. ETF XLV · price $296.41
In short — Charles River Laboratories trades at —× earnings (P/E), 23.4× forward, with a net margin of -6.0 % and revenue growth of -3 %. Read: Not (yet) profitable (valued on growth, not earnings).
Is Charles River Laboratories stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$296.41+81.6% over range
Aug 28, 25low $145.57 · high $298.58Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
75% recommend buying · 8 analysts
Valuation : Not (yet) profitable — valued on growth, not earnings
Valuation
—
P/E (price/earnings)
23.4
Forward P/E
—
PEG
5.0
Price/book (P/B)
$14.3B
Market cap
-4.83
EPS
Profitability & growth
-6.0 %
Net margin
-3 %
Revenue growth
—
Earnings growth
$3.0B
Total debt
Charles River Laboratories income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $4.0B | $486M | 12.2 % |
| 2023 | $4.1B | $475M | 11.5 % |
| 2024 | $4.0B | $10M | 0.3 % |
| 2025 | $4.0B | $-144M | -3.6 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Charles River Laboratories's P/E and is the stock undervalued? What's a good P/E?
Charles River Laboratories's P/E is — (forward 23.4). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Not (yet) profitable".
Is Charles River Laboratories profitable?
Charles River Laboratories has a net margin of -6.0 % (EPS -4.83). The company is not (yet) profitable.
Is CRL stock expensive?
Our read: "Not (yet) profitable" — valued on growth, not earnings. Cross-check with growth and sector.
💬 A question about Charles River Laboratories? The JPI assistant answers using our backtest data.
Keep exploring Charles River Laboratories